← ANALYST RATINGS · TIPRANKS
Amphastar Pharmaceuticals (AMPH): analyst forecast and price target
Analyst consensus
Hold0 Buy5 Hold1 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $22.17, the highest $30.00, the lowest $20.00. The average is −14.3% from the last price of $25.87.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $29.00 → $30.00+3.4% | Buy | +16.0% | Upgrade | 29.09.26on TipRanks 03:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $28.00 → $30.00+7.1% | Hold | +16.0% | Reiterated | 29.09.26on TipRanks 03:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $27.00 → $29.00+7.4% | Hold | +12.1% | Reiterated | 29.09.26on TipRanks 03:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $29.00 → $31.00+6.9% | Buy | +19.8% | Reiterated | 29.09.26on TipRanks 03:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $28.00 → $30.00+7.1% | Buy | +16.0% | Upgrade | 29.09.26on TipRanks 03:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $28.00 | Hold | +8.2% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $20.00 | Hold | −22.7% | Reiterated | 02.09.26on TipRanks 11:05 | +3.0%next day −0.6% · 5 days +0.1% | ↗ |
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $20.00 → $23.00+15.0% | Hold | −11.1% | Reiterated | 18.08.26on TipRanks 11:25 | +3.0%next day +1.7% · 5 days +3.2% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $20.00 | Sell | −22.7% | Reiterated | 07.08.26on TipRanks Aug 10 05:16 | +4.3%next day −2.2% · 5 days +0.2% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $20.00 | Hold | −22.7% | Reiterated | 07.08.26on TipRanks 08:20 | +4.3%next day −2.2% · 5 days +0.2% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $21.00 → $20.00−4.8% | Hold | −22.7% | Reiterated | 07.08.26on TipRanks 08:01 | +4.3%next day −2.2% · 5 days +0.2% | ↗ |
| Unknown Analyst | J.P. Morgan | $30.00 | Hold | +16.0% | Reiterated | 23.07.26on TipRanks Jul 24 21:06 | −1.0%next day −0.9% · 5 days +7.5% | ↗ |
| Dennis Ding★★★★★★★★★★#2230 · hits 58% · avg +12.3% | Jefferies | $30.00 → $22.00−26.7% | Hold | −15.0% | Downgrade | 21.04.26on TipRanks Apr 20 16:35 | −6.8%next day −2.0% · 5 days +1.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Amphastar Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $22.17 at a price of $25.81 (−14.1%); now: $22.17 at $25.87 (−14.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 6 | 7 | 7 | 7 | 7 | 5 |
| Sell | 0 | 1 | 1 | 2 | 1 | 1 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.86 (from $0.70 to $1.05). Last quarter: $0.91.
Sales
Next quarter’s sales estimate — $198M (from $184M to $207M). Last quarter: $184M.
Best top-analyst consensus in the sector · Healthcare
About Amphastar Pharmaceuticals
- CEO: Yongfeng Zhang
- Employees: 1,976
- 11570 6th Street, Rancho Cucamonga, CA, 91730, US
- www.amphastar.com
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant hum
Data from the stock’s TipRanks forecast page, read 41 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗